HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 384 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,687,064 | +31.8% | 70,342 | +24.4% | 0.01% | +25.0% |
| Q2 2023 | $2,039,037 | +146277.4% | 56,530 | +55.0% | 0.01% | +33.3% |
| Q1 2023 | $1,393 | -25.5% | 36,482 | +10.9% | 0.01% | -33.3% |
| Q4 2022 | $1,871 | -99.5% | 32,883 | +228.4% | 0.01% | +350.0% |
| Q3 2022 | $395,000 | -15.4% | 10,014 | -5.8% | 0.00% | 0.0% |
| Q2 2022 | $467,000 | +41.1% | 10,627 | +27.9% | 0.00% | 0.0% |
| Q1 2022 | $331,000 | -3.5% | 8,307 | -2.8% | 0.00% | 0.0% |
| Q4 2021 | $343,000 | +1.5% | 8,549 | +2.8% | 0.00% | 0.0% |
| Q3 2021 | $338,000 | +1200.0% | 8,313 | +1350.8% | 0.00% | – |
| Q2 2021 | $26,000 | +18.2% | 573 | +7.5% | 0.00% | – |
| Q1 2021 | $22,000 | +4.8% | 533 | +6.6% | 0.00% | – |
| Q4 2020 | $21,000 | +61.5% | 500 | 0.0% | 0.00% | – |
| Q3 2020 | $13,000 | -92.0% | 500 | -91.8% | 0.00% | -100.0% |
| Q2 2020 | $163,000 | +24.4% | 6,088 | -16.7% | 0.00% | 0.0% |
| Q1 2020 | $131,000 | +1355.6% | 7,305 | +1361.0% | 0.00% | – |
| Q4 2019 | $9,000 | – | 500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |